Consilium MedicumConsilium Medicum2075-17532542-2170Consilium Medicum9497610.26442/2075-1753_2018.5.34-39Research ArticleAtrial fibrillation in hypertrophic cardiomyopathy: modern aspects of epidemiology, risk factors, pathogenesis and medication-assisted treatmentStreltsovaA. Aanikas1985@gmail.comGudkovaA. Yaalexagood-1954@mail.ruKostarevaA. Aakostareva@hotmail.comV.A.Almazov National Medical Research CenterI.P.Pavlov First Saint Petersburg State Medical University15052018205343928122021Copyright © 2018, Consilium Medicum2018Atrial fibrillation (AF) is a particularly important arrhythmia in hypertrophic cardiomyopathy (HCM). This article describes the epidemiology of AF within the HCM population and analyses risk factors for the development of AF. The possible relation between the development of atrial fibrillation (AF) and insulin resistance in patients with HCM is also discussed. Here, we also review the outcomes associated with AF in HCM population and pharmacologic treatment strategies in this patient grouphypertrophic cardiomyopathysudden cardiac deathatrial fibrillationinsulin resistancepharmacologic treatmentгипертрофическая кардиомиопатиявнезапная сердечная смертьфибрилляция предсердийинсулинорезистентностьфармакотерапия[Authors/Task Force members, Elliott P.M, Anastasakis A, Borger M.A et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 2014; 35 (39): 2733-79. DOI: 10.1093/eurheartj/ehu284][Semsarian C, Ingles J, Maron M.S, Maron B.J. New perspectives on the prevalence of hypertrophic cardiomyopathy. J Am Coll Cardiol 2015; 65 (12): 1249-54. DOI: 10.1016/j.jacc.2015. 01.019][Maron B.J, Maron M.S, Semsarian C. Genetics of hypertrophic cardiomyopathy after 20 years: clinical perspectives. J Am Coll Cardiol 2012; 60 (8): 705-15. DOI: 10.1016/j.jacc.2012.02. 068][Lopes L.R, Zekavati A, Syrris P et al. Genetic complexity in hypertrophic cardiomyopathy revealed by high-throughput sequencing. J Med Genet 2013; 50 (4): 228-39. DOI: 10.1136/jmedgenet-2012-101270][Kassem H.Sh, Azer R.S, Saber-Ayad M et al. Early results of sarcomeric gene screening from the Egyptian National BA-HCM Program. J Cardiovasc Translat Res 2013; 6 (1): 65-80. DOI: 10.1007/s12265-012-9425-0][Van Driest S.L, Ommen S.R, Tajik A.J et al. Yield of genetic testing in hypertrophic cardiomyopathy. Mayo Clinic Proceedings 2005; 80 (6): 739-44. DOI: 10.4065/80.6.739][Brito D, Miltenberger-Miltenyi G, Vale Pereira S et al. Sarcomeric hypertrophic cardiomyopathy: genetic profile in a Portuguese population. Rev Port Cardiol 2012; 31 (9): 577-87. DOI: 10.1016/j.repc.2011.12.020][Morita H, Rehm H.L, Menesses A et al. Shared genetic causes of cardiac hypertrophy in children and adults. N Engl J Med 2008; 358 (18): 1899-908. DOI: 10.1056/NEJMoa075463][Alfares A.A, Kelly M.A, McDermott G et al. Results of clinical genetic testing of 2,912 probands with hypertrophic cardiomyopathy: expanded panels offer limited additional sensitivity. Genet Med 2015; 17 (11): 880-8. DOI: 10.1038/gim.2014.205.][Hodatsu A, Konno T, Hayashi K et al. Compound heterozygosity deteriorates phenotypes of hypertrophic cardiomyopathy with founder MYBPC3 mutation: evidence from patients and zebrafish models. Am J Physiol - Heart and Circulatory Physiology 2014; 307 (11): H1594-H1604. DOI: 10.1152/ajpheart.00637.2013][Girolami F, Ho C.Y, Semsarian C et al. Clinical features and outcome of hypertrophic cardiomyopathy associated with triple sarcomere protein gene mutations. J Am Coll Cardiol 2010; 55 (14): 1444-53. DOI: 10.1016/j.jacc.2009.11.062][Li L, Bainbridge M.N, Tan Y et al. A potential oligogenic etiology of hypertrophic cardiomyopathy: a classic single-gene disorder. Circulation Res 2017; 120: 1084-90. DOI: 10.1161/CIRCRESAHA.116.310559][Cooper R.M, Raphael C.E, Liebregts M et al. New Developments in Hypertrophic Cardiomyopathy. Can J Cardiol 2017; 33 (10): 1254-65. DOI: 10.1016/j.cjca.2017.07.007][Marian A.J, Braunwald E. Hypertrophic Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy. Circulation Res 2017; 121 (7): 749-70. DOI: 10.1161/CIRCRESAHA.117.311059][Eriksson M.J, Sonnenberg B, Woo A et al. Long-term outcome in patients with apical hypertrophic cardiomyopathy. J Am Coll Cardiol 2002; 39 (4): 638-45. DOI: 10.1016/S0735-1097(01)01778-8][Binder J, Attenhofer Jost C.H, Klarich K.W et al. Apical hypertrophic cardiomyopathy: prevalence and correlates of apical outpouching. J Am Soc Echocardiogr 2011; 24 (7): 775-81. DOI: 10.1016/j.echo.2011.03.002][D’Amato R, Tomberli B, Castelli G et al. Prognostic value of N-terminal pro-brain natriuretic Peptide in outpatients with hypertrophic cardiomyopathy. Am J Cardiol 2013; 112 (8): 1190-6. DOI: 10.1016/j.amjcard.2013.06.018][Guttmann O.P, Rahman M.S, O'Mahony C et al. Atrial fibrillation and thromboembolism in patients with hypertrophic cardiomyopathy: systematic review. Heart 2014; 100 (6): 465-72. DOI: 10.1136/heartjnl-2013-304276][Rowin E.J, Hausvater A, Link M. et al. Clinical Profile and Consequences of Atrial Fibrillation in Hypertrophic Cardiomyopathy. Circulation 2017. DOI: 10.1161/CIRCULATIONAHA.117.029267][European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery, Camm A.J, Kirchhof P, Lip G.Y et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31 (19): 2369-29. DOI: 10.1093/eurheartj/ehq278][Lloyd-Jones D.M, Wang T.J, Leip E.P et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation 2004; 110 (9): 1042-6. DOI: 10.1161/01.CIR. 0000140263.20897.42][Kirchhof P, Benussi S, Kotecha D et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016; 37 (38): 2893-962. DOI: 10.1093/eurheartj/ehw210][Camm C.F, Camm A.J. Atrial Fibrillation and Anticoagulation in Hypertrophic Cardiomyopathy. Arrhythm and Electrophysiol Rev 2017; 6 (2): 63-8. DOI: 10.15420/aer.2017.4.2][Крылова Н.С., Демкина А.Е., Хашиева Ф.М. и др. Фибрилляция и трепетание предсердий у больных с гипертрофической кардиомиопатией. Рос. кардиол. журн. 2015; 5: 64-70. DOI: 10.15829/1560-4071-2015-5-64-70.][Gruver E.J, Fatkin D, Dodds G.A et al. Familial hypertrophic cardiomyopathy and atrial fibrillation caused by Arg663His beta-cardiac myosin heavy chain mutation. Am J Cardiol 1999; 83 (12A): 13H-18H. DOI: 10.1016/s0002-9149(99)00251-9][Ogimoto A, Hamada M, Nakura J et al. Relation between angiotensin-converting enzyme II genotype and atrial fibrillation in Japanese patients with hypertrophic cardiomyopathy. J Hum Genet 2002; 47 (4): 184-9. DOI: 10.1007/s100380200021][Spirito P, Autore C, Formisano F et al. Risk of sudden death and outcome in patients with hypertrophic cardiomyopathy with benign presentation and without risk factors. Am J Cardiol 2014; 113 (9): 1550-5. DOI: 10.1016/j.amjcard.2014.01.435][Tani T, Tanabe K, Ono M et al. Left atrial volume and the risk of paroxysmal atrial fibrillation in patients with hypertrophic cardiomyopathy. J Am Soc Echocardiogr 2004; 17 (6): 644-8. DOI: 10.1016/j.echo.2004.02.010][Olivotto I, Cecchi F, Casey S.A et al. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation 2001; 104 (21): 2517-24. DOI: 10.1161/hc4601.097997][Losi M.A, Betocchi S, Aversa M et al. Determinants of atrial fibrillation development in patients with hypertrophic cardiomyopathy. Am J Cardiol 2004; 94 (1): 895-900. DOI: 10.1016/j.amjcard.2004.06.024][Siontis K.C, Geske J.B, Ong K et al. Atrial fibrillation in hypertrophic cardiomyopathy: prevalence, clinical correlations, and mortality in a large high-risk population. J Am Heart Association 2014; 3 (3): e001002. DOI: 10.1161/JAHA.114.001002][Doesch C, Lossnitzer D, Rudic B et al. Right ventricular and right atrial involvement can predict atrial fibrillation in patients with hypertrophic cardiomyopathy? Int J Med Sci 2016; 13 (1): 1-7. DOI: 10.7150/ijms.13530][Autore C, Bernabo P, Barilla C.S et al. The prognostic importance of left ventricular outflow obstruction in hypertrophic cardiomyopathy varies in relation to the severity of symptoms. J Am Coll Cardiol 2005; 45 (7): 1076-80. DOI: 10.1016/j.jacc.2004.12.067][Maron B.J, Olivotto I, Spirito P et al. Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population. Circulation 2000; 102 (8): 858-64. DOI: 10.1161/01.CIR.102.8.858][Yang W.I, Shim C.Y, Kim Y.J et al. Left atrial volume index: a predictor of adverse outcome in patients with hypertrophic cardiomyopathy. J Am Soc Echocardiogr 2009; 22 (12): 1338-43. DOI: 10.1016/j.echo.2009.09.016][Desai M.Y, Bhonsale A, Smedira N.G et al. Predictors of long-term outcomes in symptomatic hypertrophic obstructive cardiomyopathy patients undergoing surgical relief of left ventricular outflow tract obstruction. Circulation 2013; 128 (3): 209-16. DOI: 10.1161/CIRCULATIONAHA.112.000849][Ohe T. Results from the Kochi RYOMA Study. Atrial fibrillation is a major risk of morbidity in patients with hypertrophic cardiomyopathy. Сirculation J 2009; 73 (9): 1589-90. DOI: 10.1253/circj.CJ-09-0433][Tian T, Wang Y, Sun K et al. Clinical profile and prognostic significance of atrial fibrillation in hypertrophic cardiomyopathy. Cardiology 2013; 126 (4): 258-64. DOI: 10.1159/000354953][Ash-Bernal R, Peterson L.R. The cardiometabolic syndrome and cardiovascular disease. J Cardiometabolic Syndrome. 2006; 1 (1): 25-8. DOI: 10.1111/j.0197-3118.2006.05452.x][Umetani K, Kodama Y, Nakamura T et al. High prevalence of paroxysmal atrial fibrillation and/or atrial flutter in metabolic syndrome. Circulation J 2007; 71 (2): 252-5. DOI: 10.1253/circj.71.252][Watanabe H, Tanabe N, Watanabe T et al. Metabolic syndrome and risk of development of atrial fibrillation. The Niigata preventive medicine study. Circulation 2008; 117 (10): 1255-60. DOI: 10.1161/CIRCULATIONAHA.107.744466][ВНОК. Национальные рекомендации по диагностике и лечению метаболического синдрома. Кардиоваск. терапия и профилактика. 2007; 6 (6), Прил. 2.][Баранова Е.И., Листопад О.В., Соболева А.В., Яцук Д.И. Гипертоническая болезнь и другие причины фибрилляции предсердий у пациентов, госпитализированных в терапевтическую клинику. Кардиология: новости, мнения, обучение. 2013; 1: 85-92.][Nguyen J.T, Benditt D.G. Atrial fibrillation susceptibility in metabolic syndrome: simply the sum of its parts? Circulation 2008; 117 (10): 1249-51. DOI: 10.1161/CIRCULATIONAHA.107.760777][Russo C, Jin Z, Homma S et al. Effect of Obesity and Overweight on Left Ventricular Diastolic Function: a Community-based Study in an Elderly Cohort. J Am Col Cardiol 2011; 57 (12): 1368-74. DOI: 10.1016/j.jacc.2010.10.042][Ruige J.B, Assendelft W.J, Dekker J.M et al. Insulin and risk of cardiovascular disease: a meta-analysis. Circulation 1998; 97 (10): 996-1001. DOI: 10.1161/01.CIR.97.10.996][Savage D.B, Petersen K.F, Shulman G.I. Mechanisms of insulin resistance in humans and possible links with inflammation. Hypertension 2005; 45 (5): 828-33. DOI: 10.1161/01.HYP. 0000163475.04421.e4][Chung M.K, Martin D.O, Sprecher D et al. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation 2001; 104 (24): 2886-91. DOI: 10.1161/hc4901.101760][Mihm M.J, Yu F, Carnes C.A et al. Impaired myofibrillar energetics and oxidative injury during human atrial fibrillation. Circulation 2001; 104 (2): 174-80. DOI: 10.1161/01.CIR.104.2.174][Murakami K, Shigematsu Y, Hamada M, Higaki J. Insulin resistance in patients with hypertrophic cardiomyopathy. Circulation J 2004; 68 (7): 650-5. DOI: 10.1253/circj.68.650][Harano Y, Suzuki M, Koyama Y et al. Multifactorial insulin resistance and clinical impact in hypertension and cardiovascular diseases. J Diabetes Complications 2002; 16 (1): 19-23. DOI: 10.1016/S1056-8727(01)00192-1][Shigematsu Y, Hamada M, Nagai T et al. Risk for atrial fibrillation in patients with hypertrophic cardiomyopathy: association with insulin resistance. J Cardiol 2011; 58 (1): 18-25. DOI: 10.1016/j.jjcc.2011.03.001][Gersh B.J, Maron B.J, Bonow R.O et al. 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011; 124: e783-831. DOI: 10.1161/CIR.0b013e318223e2bd][Cooper R.M, Raphael C.E, Liebregts M et al. New Developments in Hypertrophic Cardiomyopathy. Can J Cardiol 2017; 33 (10): 1254-65. DOI: 10.1016/j.cjca.2017.07.007][Moore J.C, Trager L, Anzia L.E et al. Dofetilide for suppression of atrial fibrillation in hypertrophic cardiomyopathy: A case series and literature review. Pacing ClinElectrophysiol 2018. DOI: 10.1111/pace.13310.][Ammirati E, Contri R, Coppini R et al. Pharmacological treatment of hypertrophic cardiomyopathy: current practice and novel perspectives. Eur J Heart Failure 2016; 18 (9): 1106-18. DOI: 10.1002/ejhf.541][Quintana E, Cox J.L. Surgical management of atrial fibrillation at the time of septal myectomy. Ann Cardiothoracic Surg 2017; 6 (4): 386-93. DOI: 10.21037/acs.2017.05.08.][January C.T, Wann L.S, A.J.S Calkins H et al.; ACC/AHA Task Force Members. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation 2014; 130: e199-267. DOI: 10.1161/CIR.0000000000000041][JCS Joint Working Group. Guidelines for diagnosis and treatment of patients with hypertrophic cardiomyopathy (JCS 2012) - digest version. Circulation J 2016; 80: 753-74. DOI: 10.1253/circj.CJ-66-0122][JCS Joint Working Group. Guidelines for pharmacotherapy of atrial fibrillation (JCS 2013). Circulation J 2014; 78: 1997-2021. DOI: 10.1253/circj.CJ-66-0092][Лебедев Д.С., Михайлов Е.Н., Гуреев С.В. и др. Катетерная аблация хронической фибрилляции предсердий у пациента с гипертрофической кардиомиопатией. Вестн. аритмологии. 2008; 51: 72-4.][Ikenaga H, Nakano Y, Oda N et al. Radiofrequency catheter ablation is effective for atrial fibrillation patients with hypertrophic cardiomyopathy by decreasing left atrial pressure. J Arrhythmia 2017; 33 (4): 256-61. DOI: 10.1016/j.joa.2016.08.006][Providencia R, Elliott P, Patel K et al. Catheter ablation for atrial fibrillation in hypertrophic cardiomyopathy: a systematic review and meta-analysis. Heart (British Cardiac Society) 2016; 102 (19): 1533-43. DOI: 10.1136/heartjnl-2016-309406][Maagh P, Plehn G, Christoph A et al. Impact of Cryoballoon Ablation in Hypertrophic Cardiomyopathy-related Heart Failure due to Paroxysmal Atrial Fibrillation. A Comparative Case Series. Int J Med Sci 2016; 13 (9): 664-72. DOI: 10.7150/ijms.16181][Бокерия Л.А., Бокерия О.Л., Климчук И.Я., Санакоев М.К. Хирургическая коррекция обструктивной гипертрофической кардиомиопатии с SAM-синдромом и фибрилляцией предсердий. Анналы аритмологии. 2016; 13 (4): 216-21. DOI: 10.15275/annaritmol.2016.4.4]